- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Development of therapeutic antibody for the treatment of myasthenia gravis | ||||||
| Antibody | Myasthenia gravis | Disclosure after confidentiality agreement | Candidate | Medytox Inc. | RS-2023-00283006 | ||
| 2 | Bone-delivered therapeutic antibody for osteoporosis based on clinically verified, innovative mode of action | ||||||
| Antibody | Osteoporosis | Cathepsin K | Hit | Ewha Women's University | HN21C0317 | ||